Bnipspd

Bnipspd

SCHEMBL13909975

O=C1c2cccc3cccc(c23)C(=O)N1CCCNCCCCNCCCNCCCN1C(=O)c2cccc3cccc(c23)C1=O

nearest known ligand 0.91

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 3/20 0.91
HEXA P06865 7/20 0.77
HEXB P07686 7/20 0.77
OGA O60502 1/20 0.77
KMT2A Q03164 3/20 0.60
MEN1 O00255 2/20 0.60
POLB P06746 2/20 0.60
NR1I2 O75469 1/20 0.60
AHR P35869 1/20 0.60
RAD52 P43351 1/20 0.60
RCE1 Q9Y256 1/20 0.60
CYP3A4 P08684 1/20 0.57
NFKB1 P19838 1/20 0.57
HSD17B10 Q99714 1/20 0.57
ALDH1A1 P00352 3/20 0.57
HDAC3 O15379 1/20 0.57
LTA4H P09960 1/20 0.57
HDAC4 P56524 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC7 Q8WUI4 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13909963 0.98 SIRT1 (0.94) SIRT1HEXAHEXBOGAKMT2A
SCHEMBL13909979 0.98 SIRT1 (0.88) SIRT1HEXAHEXBOGAKMT2A
Bnipdpta SCHEMBL13909966 0.98 SIRT1 (0.88) SIRT1HEXAHEXBOGAKMT2A
SCHEMBL13909960 0.97 SIRT1 (0.97) SIRT1HEXAHEXBOGAKMT2A
Bnipdaoct SCHEMBL12522398 0.97 SIRT1 (0.97) SIRT1HEXAHEXBOGAKMT2A
SCHEMBL13909968 0.97 SIRT1 (0.97) SIRT1HEXAHEXBOGAKMT2A
SCHEMBL13909961 0.97 SIRT1 (0.97) SIRT1HEXAHEXBOGAKMT2A
Bnipdadec SCHEMBL13909967 0.97 SIRT1 (0.97) SIRT1HEXAHEXBOGAKMT2A
Bnipdanon SCHEMBL13909969 0.97 SIRT1 (0.97) SIRT1HEXAHEXBOGAKMT2A
SCHEMBL13909962 0.97 SIRT1 (0.97) SIRT1HEXAHEXBOGAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350036-B2 Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity UNIVERSIDADE DO PORTO (PT) 2013-01-08 US disclosed
US-20090062329-A1 BISNAPHTHALIMIDOPROPYL DERIVATIVE COMPOUNDS WITH ANTI-PARASITE AND ANTI-CANCER ACTIVITY UNIVERSIDADE DO PORTO (PT) 2009-03-05 US disclosed
US-20090062329-A1 BISNAPHTHALIMIDOPROPYL DERIVATIVE COMPOUNDS WITH ANTI-PARASITE AND ANTI-CANCER ACTIVITY UNIVERSIDADE DO PORTO (PT) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062329-A1 BISNAPHTHALIMIDOPROPYL DERIVATIVE COMPOUNDS WITH ANTI-PARASITE AND ANTI-CANCER ACTIVITY DCPS, SI, MYADM SIRT1 2192/4885HEXA 1154/4885HEXB 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.